Evaluation of effects of eucalyptus tablets on the process of covid 19 disease

Evaluation of therapeutic effects of oral eucalyptus tablets on the treatment process of patients with Covid 19 infection.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200913048701N1

Enrollment

Registered

2020-09-22

Start date

2020-09-22

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19

Interventions

Intervention 1: Intervention group: Patients undergoing intervention with Eucalyptus soft oral capsule from Barij Essential Oil Company containing Eucalyptus essential oil (Eucalyptus globulus) Active

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients between 40 and 60 years of age with new coronavirus infection 2019 who have been admitted to Firoozabadi Hospital.

Exclusion criteria

Exclusion criteria: Age over 60 years Age under 40 years No hospitalization No infection with coronavirus 2019

Design outcomes

Primary

Measure	Time frame
Blood oxygen level (SPO2%). Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Pulse oximeter device.;Inflammatory index CRP. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;Cough. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Qualitative (mild-moderate-severe).;Blood lymphocyte count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;White blood cell count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.	—

Measure

Time frame

Blood oxygen level (SPO2%). Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Pulse oximeter device.;Inflammatory index CRP. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;Cough. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Qualitative (mild-moderate-severe).;Blood lymphocyte count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.;White blood cell count. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: blood test.

—

Secondary

Measure	Time frame
The rate of disease progression. Timepoint: Before the intervention, and 3, 5 and 7 days after the intervention. Method of measurement: Researcher checklist.;Duration of hospitalization. Timepoint: Before the intervention and 7 days after the intervention. Method of measurement: Researcher checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Shirazi

Iran University of Medical Sciences

shirazi.h@iums.ac.ir+98 21 3625 6451

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026